Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Increased levels of MMP-3, MMP-9 and MPO represent predictors of in-stent restenosis, while increased levels of ADMA, LCAT, ApoE and ApoD predict bare metal stent patency

L. Pleva, P. Kusnierova, P. Plevova, J. Zapletalova, M. Karpisek, L. Faldynova, P. Kovarova, P. Kukla

. 2015 ; 159 (4) : 586-594. [pub] 20150903

Language English Country Czech Republic

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc17004320

AIMS: We sought to identify biochemical predictors that indicate susceptibility to in-stent restenosis (ISR) after coronary artery bare-metal stenting. METHODS: A total of 111 consecutive patients with post-percutaneous coronary intervention (PCI) in-stent restenosis of a target lesion within 12 months were matched for age, sex, vessel diameter, and diabetes with 111 controls without post-PCI ISR. Plasma or serum levels of biochemical markers were measured: matrix metalloproteinases (MMP) 2, 3, 9; myeloperoxidase (MPO); asymmetric dimethylarginine (ADMA); lipoprotein (a) (Lp[a]); apolipoproteins E and D (ApoE and D); and lecitin-cholesterol acyltransferase (LCAT). Multivariable logistic regression association tests were performed. RESULTS: Increased plasma MMP-3 (OR: 1.013; 95% CI: 1.004-1.023; P = 0.005), MMP-9 (OR: 1.014; 95% CI: 1.008-1.020; P < 0.0001) or MPO (OR: 1,003; 95% CI: 1.001-1.005; P = 0.002) was significantly associated with increased risk of ISR. Increased levels of ADMA (OR: 0.212; 95% CI: 0.054-0.827; P = 0.026), ApoE (OR: 0.924; 95% CI: 0.899-0.951; P < 0.0001), ApoD (OR: 0.919; 95% CI: 0.880-0.959; P = 0.0001), or LCAT (OR: 0.927; 95% CI: 0.902-0.952; P < 0.0001) was associated with risk reduction. No correlation was found between plasma MMP-2 or Lp (a) and ISR risk. CONCLUSIONS: Increased levels of MMP-3, MMP-9, and MPO represent predictors of ISR after bare-metal stent implantation. In contrast, increased ADMA, LCAT, and Apo E and D indicate a decreased in-stent restenosis occurrence.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17004320
003      
CZ-PrNML
005      
20240312074558.0
007      
ta
008      
170127s2015 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2015.037 $2 doi
024    7_
$a 10.5507/bp.2015.037 $2 doi
035    __
$a (PubMed)26365933
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Pleva, Leoš $u Department of Clinical Studies, Faculty of Medicine, University of Ostrava, Czech Republic; Department of Cardiovascular Diseases, University Hospital Ostrava $7 xx0171469
245    10
$a Increased levels of MMP-3, MMP-9 and MPO represent predictors of in-stent restenosis, while increased levels of ADMA, LCAT, ApoE and ApoD predict bare metal stent patency / $c L. Pleva, P. Kusnierova, P. Plevova, J. Zapletalova, M. Karpisek, L. Faldynova, P. Kovarova, P. Kukla
520    9_
$a AIMS: We sought to identify biochemical predictors that indicate susceptibility to in-stent restenosis (ISR) after coronary artery bare-metal stenting. METHODS: A total of 111 consecutive patients with post-percutaneous coronary intervention (PCI) in-stent restenosis of a target lesion within 12 months were matched for age, sex, vessel diameter, and diabetes with 111 controls without post-PCI ISR. Plasma or serum levels of biochemical markers were measured: matrix metalloproteinases (MMP) 2, 3, 9; myeloperoxidase (MPO); asymmetric dimethylarginine (ADMA); lipoprotein (a) (Lp[a]); apolipoproteins E and D (ApoE and D); and lecitin-cholesterol acyltransferase (LCAT). Multivariable logistic regression association tests were performed. RESULTS: Increased plasma MMP-3 (OR: 1.013; 95% CI: 1.004-1.023; P = 0.005), MMP-9 (OR: 1.014; 95% CI: 1.008-1.020; P < 0.0001) or MPO (OR: 1,003; 95% CI: 1.001-1.005; P = 0.002) was significantly associated with increased risk of ISR. Increased levels of ADMA (OR: 0.212; 95% CI: 0.054-0.827; P = 0.026), ApoE (OR: 0.924; 95% CI: 0.899-0.951; P < 0.0001), ApoD (OR: 0.919; 95% CI: 0.880-0.959; P = 0.0001), or LCAT (OR: 0.927; 95% CI: 0.902-0.952; P < 0.0001) was associated with risk reduction. No correlation was found between plasma MMP-2 or Lp (a) and ISR risk. CONCLUSIONS: Increased levels of MMP-3, MMP-9, and MPO represent predictors of ISR after bare-metal stent implantation. In contrast, increased ADMA, LCAT, and Apo E and D indicate a decreased in-stent restenosis occurrence.
650    _2
$a senioři $7 D000368
650    _2
$a apolipoproteiny D $x metabolismus $7 D053399
650    _2
$a apolipoproteiny E $x metabolismus $7 D001057
650    _2
$a arginin $x analogy a deriváty $x metabolismus $7 D001120
650    _2
$a biologické markery $x metabolismus $7 D015415
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a koronární restenóza $x diagnóza $x patofyziologie $7 D023903
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a okluze cévního štěpu $x diagnóza $x patofyziologie $7 D006083
650    _2
$a lidé $7 D006801
650    _2
$a lipoprotein (a) $x metabolismus $7 D017270
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a matrixová metaloproteinasa 3 $x metabolismus $7 D019278
650    _2
$a matrixová metaloproteinasa 9 $x metabolismus $7 D020780
650    _2
$a lidé středního věku $7 D008875
650    _2
$a koronární angioplastika $7 D062645
650    _2
$a peroxidasa $x metabolismus $7 D009195
650    _2
$a lecitincholesterolacyltransferasa $x metabolismus $7 D007862
650    12
$a stenty $7 D015607
650    _2
$a průchodnost cév $x fyziologie $7 D014654
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kušnierová, Pavlína, $u Department of Biomedical Sciencies, Faculty of Medicine, University of Ostrava; Department of Laboratory Medicine, University Hospital Ostrava $d 1978- $7 xx0140526
700    1_
$a Plevová, Pavlína $u Department of Biomedical Sciencies, Faculty of Medicine, University of Ostrava; Department of Medical Genetics, University Hospital Ostrava $7 xx0044813
700    1_
$a Zapletalová, Jana $u Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University Olomouc $7 xx0111614
700    1_
$a Karpíšek, Michal $u R&D Department, Biovendor Inc., Brno $7 xx0107472
700    1_
$a Faldynová, Lucie $u Department of Biomedical Sciencies, Faculty of Medicine, University of Ostrava; Department of Medical Genetics, University Hospital Ostrava $7 xx0314699
700    1_
$a Kovářová, Petra. $u Department of Biomedical Sciencies, Faculty of Medicine, University of Ostrava; Blood Center, University Hospital of Ostrava $7 xx0230388
700    1_
$a Kukla, Pavel $u Department of Cardiovascular Diseases, University Hospital Ostrava $7 xx0114113
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $x 1213-8118 $g Roč. 159, č. 4 (2015), s. 586-594
856    41
$u http://biomed.papers.upol.cz/ $y domovská stránka časopisu
910    __
$a ABA008 $b A 1502 $c 958 $y 4 $z 0
990    __
$a 20170127 $b ABA008
991    __
$a 20240312074555 $b ABA008
999    __
$a ok $b bmc $g 1192535 $s 964936
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 159 $c 4 $d 586-594 $e 20150903 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20170127

Find record

Citation metrics

Archiving options